生血合剂治疗再生障碍性贫血的临床研究

作者	单位
周永明	ZHOU Yongming, HUANG Zhenqiao,HUANG Tao, et al Affiliated Yueyang Hospital, Shanghai University of TCM, Shanghai (200437
黄振翘	ZHOU Yongming, HUANG Zhenqiao,HUANG Tao, et al Affiliated Yueyang Hospital, Shanghai University of TCM, Shanghai (200437
黄韬	ZHOU Yongming, HUANG Zhenqiao,HUANG Tao, et al Affiliated Yueyang Hospital, Shanghai University of TCM, Shanghai (200437
薛志忠	ZHOU Yongming, HUANG Zhenqiao,HUANG Tao, et al Affiliated Yueyang Hospital, Shanghai University of TCM, Shanghai (200437
周韶虹	ZHOU Yongming, HUANG Zhenqiao,HUANG Tao, et al Affiliated Yueyang Hospital, Shanghai University of TCM, Shanghai (200437
陆嘉惠	ZHOU Yongming, HUANG Zhenqiao,HUANG Tao, et al Affiliated Yueyang Hospital, Shanghai University of TCM, Shanghai (200437
李艳红	ZHOU Yongming, HUANG Zhenqiao,HUANG Tao, et al Affiliated Yueyang Hospital, Shanghai University of TCM, Shanghai (200437

摘要点击次数: 1516

全文下载次数: 938

中文摘要:

目的：观察生血合剂治疗再生障碍性贫血（简称再障）的临床疗效，探讨可能的疗效机理。方法：治疗组８４例，脾肾阳虚型用生血Ⅰ号合剂、脾肾阴虚型用生血Ⅱ号合剂治疗；对照组３０例用康力龙治疗，观察临床疗效和多项实验指标的变化。结果：治疗组基本治愈率、缓解率、总有效率分别为２１．４３％、２７．３８％、８６．９０％，对照组依次为３．３３％、２０．００％、５６．６７％，两组总有效率比较有显著性差异（Ｐ＜０．０５），治疗组疗效明显优于对照组，而且未见肝功能损害等不良反应。经生血合剂治疗后，大多数患者在临床症状改善的同时，外周血象明显升高、Ｔ淋巴细胞亚群比例趋向正常、自然杀伤细胞活性增加、白介素２产生减少、骨髓增生程度明显好转，均有统计学意义。结论：生血合剂治疗再障疗效良好，安全无毒，其疗效机制可能是通过调整免疫，促进造血功能的恢复来实现的。

英文摘要:

To observe the clinical effect of Shengxue mixture (SXM) in treating aplastic anemia, and studied its mechanism. Methods: Eighty-four patients of the treated group, those with Spleen-Kidney Yang deficiency Syndrome and Spleen-Kidney Yin deficiency Syndrone were treated with SXM-A and SXM-B respectively, and 30 patients of the control group were treated with Stanozolol. The clinical effect and several experimental parameters were also observed. Results: The basic cure rate, remission rate, total effective rate of the treated and control group were 21. 43%, 27.38%, 86.90% and 3.33%, 20.00%, 56.67% respectively, the difference between 2 groups was significant (P<0.05, P<0.01). The effect of the treated group was obviously better than that of the control group. While the patients’ symptoms were alleviated, the peripheral blood cells increased, the ratio of T lymphocyte subsets tended to balance, the level of natural killer cells activity increased, interleukin 2 reduced, and the reproduction of the bone marrow were markedly improved in most of the patients treated by SXM. Conclusion: SXM is an effective and safe drug for aplastic anemia. Its mechanism might be regulating the immune function, which facilitated the recovery of the bone marrow hematopoiesis function.

关闭